Shield Therapeutics (LON:STX)‘s stock had its “under review” rating restated by equities research analysts at Peel Hunt in a report issued on Friday.
Separately, Liberum Capital reaffirmed an “under review” rating on shares of Shield Therapeutics in a research report on Monday, February 5th.
Shares of LON STX opened at GBX 19.50 ($0.27) on Friday. Shield Therapeutics has a 12-month low of GBX 15 ($0.21) and a 12-month high of GBX 168.50 ($2.37).
ILLEGAL ACTIVITY WARNING: “Peel Hunt Reiterates “Under Review” Rating for Shield Therapeutics (STX)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/peel-hunt-reiterates-under-review-rating-for-shield-therapeutics-stx.html.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.